KLP Kapitalforvaltning AS Decreases Stake in Collegium Pharmaceutical, Inc. $COLL

KLP Kapitalforvaltning AS lowered its position in shares of Collegium Pharmaceutical, Inc. (NASDAQ:COLL - Free Report) by 35.1% in the second quarter, according to its most recent 13F filing with the SEC. The firm owned 19,600 shares of the specialty pharmaceutical company's stock after selling 10,600 shares during the quarter. KLP Kapitalforvaltning AS owned about 0.06% of Collegium Pharmaceutical worth $580,000 as of its most recent filing with the SEC.

Other institutional investors have also modified their holdings of the company. Allspring Global Investments Holdings LLC purchased a new stake in shares of Collegium Pharmaceutical during the 1st quarter worth about $244,000. Amundi grew its holdings in shares of Collegium Pharmaceutical by 302.1% during the 1st quarter. Amundi now owns 62,592 shares of the specialty pharmaceutical company's stock worth $1,816,000 after purchasing an additional 47,024 shares during the period. Janney Montgomery Scott LLC acquired a new stake in shares of Collegium Pharmaceutical in the first quarter valued at about $439,000. Fortis Capital Advisors LLC acquired a new stake in shares of Collegium Pharmaceutical in the first quarter valued at about $408,000. Finally, Nuveen LLC acquired a new stake in shares of Collegium Pharmaceutical in the first quarter valued at about $2,674,000.

Analysts Set New Price Targets

COLL has been the subject of a number of recent research reports. Zacks Research upgraded Collegium Pharmaceutical from a "hold" rating to a "strong-buy" rating in a research note on Wednesday, September 24th. Weiss Ratings reiterated a "hold (c)" rating on shares of Collegium Pharmaceutical in a research note on Wednesday, October 8th. Wall Street Zen lowered Collegium Pharmaceutical from a "strong-buy" rating to a "buy" rating in a research note on Saturday. Finally, HC Wainwright upgraded Collegium Pharmaceutical to a "strong-buy" rating and set a $44.00 target price for the company in a research note on Monday, August 11th. Two research analysts have rated the stock with a Strong Buy rating, one has given a Buy rating and two have given a Hold rating to the company. According to MarketBeat.com, the company has an average rating of "Buy" and a consensus price target of $42.33.

Insider Transactions at Collegium Pharmaceutical

In other Collegium Pharmaceutical news, Director John Gordon Freund sold 11,659 shares of the stock in a transaction that occurred on Friday, August 8th. The stock was sold at an average price of $34.36, for a total transaction of $400,603.24. Following the transaction, the director owned 23,129 shares of the company's stock, valued at $794,712.44. This trade represents a 33.51% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Also, EVP Scott Dreyer sold 16,389 shares of the stock in a transaction that occurred on Monday, August 18th. The stock was sold at an average price of $38.21, for a total value of $626,223.69. Following the transaction, the executive vice president directly owned 103,613 shares in the company, valued at approximately $3,959,052.73. This represents a 13.66% decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders sold 55,792 shares of company stock worth $2,084,207. 2.51% of the stock is currently owned by corporate insiders.

Collegium Pharmaceutical Price Performance

Shares of NASDAQ COLL opened at $33.94 on Friday. Collegium Pharmaceutical, Inc. has a fifty-two week low of $23.23 and a fifty-two week high of $39.95. The business has a 50 day moving average price of $36.28 and a two-hundred day moving average price of $31.75. The company has a quick ratio of 1.10, a current ratio of 1.18 and a debt-to-equity ratio of 3.27. The firm has a market cap of $1.07 billion, a PE ratio of 32.63 and a beta of 0.65.

Collegium Pharmaceutical (NASDAQ:COLL - Get Free Report) last released its earnings results on Wednesday, September 4th. The specialty pharmaceutical company reported $1.26 EPS for the quarter. Collegium Pharmaceutical had a return on equity of 97.28% and a net margin of 5.13%.The company had revenue of $135.55 million for the quarter. Sell-side analysts expect that Collegium Pharmaceutical, Inc. will post 5.62 earnings per share for the current fiscal year.

Collegium Pharmaceutical announced that its Board of Directors has initiated a stock repurchase program on Monday, July 7th that authorizes the company to repurchase $150.00 million in outstanding shares. This repurchase authorization authorizes the specialty pharmaceutical company to reacquire up to 15.4% of its shares through open market purchases. Shares repurchase programs are generally an indication that the company's management believes its stock is undervalued.

Collegium Pharmaceutical Profile

Collegium Pharmaceutical, Inc, a specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, and oral formulation of oxycodone for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol, indicated for the management of acute, severe, and persistent pain; Belbuca, a buccal film that contains buprenorphine; and Symproic, an oral formulation of naldemedine for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain.

Want to see what other hedge funds are holding COLL? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Collegium Pharmaceutical, Inc. (NASDAQ:COLL - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.